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Platinum(II) and ruthenium(II)-based complexes that contain imidazole, pyrrole and b-alanine subunits,
capable of recognising speciﬁc DNA base-pair sequences, have been synthesised. These polyamides, two
platinum(II), [Cl(NH3)2Pt-L6-b-Ala-Py-L4-Im]+ (HSP-2), and [Cl(NH3)2Pt-L6-b-Ala-PyPyPy-L4-ImImIm]+
(HSP-6) and two ruthenium, D and K-[b-Ala-Py-L4-Im-b-dpq-Ru(phen)2]2+ (D and K-RUP1), were
designed to recognise DNA sequences up to seven base-pairs in length. They were obtained in good yield
by a combination of solid and solution phase chemistries. The chirality of the ruthenium precursors D-
and K-[Ru(phen)2(phendo)]2+ was conserved throughout the synthesis. Characterisation was achieved
using NMR, UV–Vis and ESI-MS and CD for D- and K-RUP1. Cytotoxicity was not determined for HSP-
2 or HSP-6, due to insolubility, however the IC50 values of D and K-RUP1 were conﬁrmed to be greater
than 40 lM (at an incubation time of 48 h). LD studies indicated that the ruthenium complexes interact
with ct-DNA through a mixed binding mode, which is inﬂuenced by complex concentration and chirality.
 2012 Elsevier B.V. All rights reserved.1. Introduction
Cisplatin, carboplatin and oxaliplatin are used for the treatment
of a variety of human cancers including head, neck, ovarian, testic-
ular, lung and colorectal cancers [1]. When treatment by cisplatin
is poorly tolerated, carboplatin is used, whereas oxaliplatin is used
to treat speciﬁc cisplatin-resistant cancers [2]. Despite being efﬁ-
cient drugs, their use is restricted by dose limiting side effects, such
as nephrotoxicity, neurotoxicity and ototoxicity, and intrinsic or
acquired resistance [1,3]. There are several mechanisms which pro-
duce resistance such as decreased cellular uptake/increased drug
efﬂux, increased drug deactivation arising from increased intracel-
lular glutathione concentration and enhanced DNA adduct repair/
tolerance [3a]. These limitations drive the researcher to search
for new compounds with which to treat cancer. Producing metallo-
drugs that can target speciﬁc sequences of DNA and deliver thera-
peutic effect is an area of research at the interface of biology and
chemistry that is proving to be a challenge.
Sequence selective polyamides, capable of targeting speciﬁc
DNA sequences, have been synthesised over the past ten years.
They comprise of heterocyclic groups linked by ﬂexible bonds that
rotate, and thus conform to the contour of the minor groove of
DNA. This topological complementarity is stabilised by van der
Waals interactions between the polyamide and the groove ofll rights reserved.
: +61 2 4620 3025.
aleb), j.aldrich-wright@uws.DNA. When imidazole (Im) and/or pyrrole (Py) heterocyclic rings,
b-alanine (b-ala) and/or amino butyric acid (L4 linker) residues
(Fig. 1) are combined in speciﬁc combinations they can target spe-
ciﬁc sequences of DNA [4]. The base-pairing rules that have been
developed, relate to the anti-parallel association of the pyrrole–
imidazole polyamide to their predicted target DNA sequences
[4b]. Each pair of heterocyclic rings recognises a speciﬁc base-pair
in DNA: Im/Py and Py/Im pairings distinguish between G:C and C:G
base pairs respectively, while a combination of Py/Py, b-ala and the
L4 linker is selective for both A:T and T:A base pairs. The L4 linker
facilitates the formation of a hairpin by allowing it to fold and form
dimers with itself. The hairpin polyamides have a distinct advan-
tage in binding, achieving afﬁnities and speciﬁcities comparable
to DNA-binding proteins.
Previouslywehavesynthesised trans-chlorodiammine[N-(2-ami-
noethyl)-4-[4-(N-methylimidazole-2-carboxamido)-N-methylpyr-
role-2-carboxamido]-N-methylpyrrole-2-carboxamide]plat-
inum(II) chloride (DJ1953-2) and trans-chlorodiammine-[N-(6-
aminohexyl)-4-[4-(N-methylimidazole-2-carboxamido)-N-methyl-
pyrrole-2-carboxamido]-N-methylpyrrole-2-carboxamide]plati-
num(II) chloride (DJ1953-6) (Fig. 2) [5]. Circular dichroism (CD)
studies have shown that these complexes are capable of binding
theDNAsequenced(CATTGTCAGAC)2. Althoughneither complex af-
fected DNA melting temperatures, DJ1953-2 unwound the helix by
13. DJ1953-2 was also found to inhibit RNA synthesis in vitro. The
cytotoxicity of both metal complexes in the murine leukaemia cell
line (L1210) was also determined, with DJ1953-6 (34 lM) being
more active than DJ1953-2 (>50 lM) [5].
Fig. 1. The structures of the heterocyclic groups, Im and Py, together with b-alanine and c-aminobutyric acid linker.
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Fig. 2. The polyamide complexes DJ1953-2 (a), DJ1953-6 (b), HSP-2 (c), HSP-6 (d) and RUP1(e).
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plexes in order to investigate the principle involved in DNA recog-
nition [6], act as artiﬁcial nucleases [7], and luminescent probes for
DNA [8] and to examine electron transfer mediated by DNA [9].
Many investigations have focussed upon metallointercalators –
that is, the insertion of a planar aromatic ring system between
the stacked bases of DNA. These complexes are generally of the
form [Ru(L)2(IL)]2+, where L is a ligand such as 2,20-bipyridine or
1,10-phenanthroline (phen), and IL is a ligand capable of insertion
between the base pairs of DNA, such as dipyrido[3,2-a:20,30-
c]phenazine (dppz) or dipyrido[3,2-d:2030-f]quinoxaline (dpq) [10].
Here we report the solid phase synthesis and characterisation of
four sequence selective hairpin metallopolyamides, two plati-
num(II) complexes – [Cl(NH3)2Pt-L6-b-Ala-Py-L4-Im]+ (HSP-2),
and [Cl(NH3)2Pt-L6-b-Ala-PyPyPy-L4-ImImIm]+ (HSP-6) and two
ruthenium complexes – D and K-[b-Ala-Py-L4-Im-b-dpq-Ru(-
phen)2]2+ (D and K-RUP1) (Fig. 2). The platinum metallopolya-
mides have the potential to covalently bind whereas the
rutheniummetallopolyamides are expected to interact by a combi-
nation of intercalation and groove binding. The cytotoxicity, gua-
nosine binding and interaction of D and K-RUP1 with ct-DNA
have been investigated through linear dichroism (LD).2. Experimental
2.1. Materials
N-Methyl-1H-imidazole-2-carboxylic acid was purchased from
Bachem. (9H-ﬂuoren-9-yl)methyl chloroformate-(Fmoc), c-ami-
no-butyric acid and Fmoc-b-alanine were purchased from Fluka.
N-Methyl-1H-imidazole, N,N0-diisopropylethylamine (DIEA) and
transplatin were purchased from Sigma–Aldrich. 2-Chloro-chloro-
trityl resin, Fmoc-lysine-(Fmoc)-OH and 2-(1H-benzotriazole-1-
YL)-1,1,3,3-tetramethyluroniumhexaﬂuorophosphate (HBTU) were
purchased from Auspep, Australia. Boc-L-2,4-diaminobutyric acid-
(Fmoc) was purchased from PepTech. N-Methyl-1H-pyrrole was
purchased from AlfaAesar. Potassium tetrachloroplatinate(II) and
ruthenium(III) chloride hydrate were purchased from Precious
Metals Online. Fmoc-protected amino-caproic acid (L6) and
Fmoc-c-aminobutyric acid (L4) were bought from Merck while iso-
propanol was bought from Baxter. Ethyl acetate and anhydrous
methanol were purchased from Mallinckrodt Chemicals. ct-DNA
was purchased from Invitrogen. Dowex Monosphere 550A (OH)
was purchased from Sigma. All other solvents were of analytical
grade and were used as received from Biolab. Silica gel 60
(0.003–0.040 mm) was bought from Silicycle (Canada). Dimethyl-
sulfoxide (D6, 99.9%), acetonitrile (D3, 96–97%), acetone (D6,
99.9%), dimethylformamide (D7, 99.9%) and deuterium oxide (D2,
99.9%) were purchased from Cambridge Isotope Laboratories. The
heterocyclic N-methylimidazole and N-methylpyrrole rings for
the polyamide were synthesised then activated as previously de-
scribed [11]. 1,10-Phenanthroline-5,6-dione (phendo) was syn-
thesised using an adaptation of the method by Yanagida et al.
[12] (0.88 g, 76%). 1H NMR 400 MHz (d6-DMSO): d 9.05 (d, 2H,
J = 3.23 Hz); 8.45 (d, 2H, J = 7.47 Hz); 7.74 (t, 2H, J = 5.88 Hz). Full
method is in the Supplementary data. All other reagents and sol-
vents were used as received unless otherwise stated.2.2. Instruments and physical measurements
NMR spectra were obtained on a 300 MHz Varian Mercury or a
400 MHz Bruker Avance spectrometer, either in d6-DMSO, d7-DMF
or D2O, referenced internally to the solvent. NMR experiments
were run at 35 C for DMSO and 25 C for D2O/DMF unless other-wise stated. 195Pt NMR were externally referenced to K2PtCl4
(1631 ppm) [13].
Positive ion ESI mass spectra were acquired using a Micromass
(Wyntheshawe, UK) Quattro Micro™ spectrometer equipped with
a Z-spray probe. Solutions containing concentrations ranging be-
tween 10 and 50 lM were injected into the instruments at a ﬂow
rate of 10 lL min1. The source and desolvation temperatures were
150 and 120 C, respectively. The capillary tip potential and cone
voltage were 2500 and 50 V, respectively. Between 10 and 50
acquisitions were summed to obtain spectra, which were cali-
brated against a standard CsI solution (750 mM) over the same
m/z range. CD and LD spectra were recorded on a Jasco J-810 spec-
tropolarimeter at room temperature. Samples were collected be-
tween 190 and 600 nm. Machine assisted synthesis was
performed on a Symphony Quartet 3.21 protein synthesiser on a
0.28 mmol scale. Each cycle of monomer addition involved a
DCM wash (10 mL), a DMF wash (10 mL) and deprotection with
20% piperidine/DMF (10 mL). Activated acids were added manu-
ally to the reaction vessel at the end of a deprotection cycle. Once
the required molecule had been constructed, the resin was washed
with copious amounts of DMF and DCM and dried for 1 h under
N2(g).
2.3. Synthesis of platinum(II) precursors
2.3.1. Synthesis of Pt-L6-NHBoc
Transplatin (2.50 g, 8.33 mmol) and silver nitrate (1.27 g,
7.49 mmol) in DMF (100 mL) were stirred in the dark under N2(g)
for 12 h. The mixture was ﬁltered and added to a solution of tert-
butyl-6-aminohexylcarbamate [14] (2.00 g, 9.26 mmol) in DMF
(30 mL). The solution was stirred in the dark under N2(g) for 18 h.
The solvent was removed under reduced pressure, acetone
(5 mL) was added and the mixture was kept at 4 C overnight.
The precipitate that formed was ﬁltered and re-suspended in
methanol (70 mL). This mixture was ﬁltered and the ﬁltrate was
evaporated under reduced pressure to obtain Pt-L6-NH.Boc
(2.74 g, 76%) as a yellow/white powder. 1H NMR 300 MHz (d2-
D2O): d 2.93 (t, 2H, J = 6.1 Hz), 2.55 (bm, 2H), 1.57 (bm, 2H), 1.3
(bp, 6H). 195Pt NMR 85 MHz (d7-DMF): 2423 (s).
2.3.2. Synthesis of Pt-L6-NH2
Pt-L6-NH.Boc (0.20 g, 0.39 mmol) was dissolved in methanol
(8 mL) before HCl (4 M, 7 mL) was added and the mixture stirred
for 48 h. The solvent was evaporated under reduced pressure to ob-
tain a yellow solid. Salt conversion was carried out using Dowex-
OH to obtain the product as a white solid (0.14 g, 87%). 1H NMR
300 MHz (d6-DMSO): d 7.85 (s, 2H), 5.42 (s, 2H), 4.01(s, 6H), 2.75
(t, 2H, J = 6.1 Hz), 2.56 (bp, 2H), 1.56 (bp, 4H), 1.30 (bp, 4H); 195Pt
NMR 85 MHz (d7-DMF): 2415 (bs).
2.4. Synthesis and resolution of ruthenium(II) precursors
2.4.1. Synthesis of [Ru(phen)2Cl2]
An adaptation of the method by Hiort was used [15] to obtain
the black crystallised product (1.3 g, 26%). 1H NMR 400 MHz (d3-
acetonitrile): d 8.69 (d, 4H, J = 7.51 Hz); 8.31 (s, 4H, J = 7.51 Hz);
8.10 (d, 4H, J = 7.51 Hz), 7.62 (t, 4H, J = 5.53 Hz).
2.4.2. Synthesis of [Ru(phen)2phendo]Cl2
An adaptation of the method by Hiort et al. [15] was used to
synthesise this complex (0.8 g, 94%). 1H NMR 400 MHz (d6-ace-
tone): d 8.9 (d, 1H, J = 8.15 Hz); 8.84 (d, 1H, J = 8.15 Hz); 8.74 (d,
1H, J = 4.88 Hz); 8.68 (d, 1H, J = 7.87 Hz); 8.49 (q, 2H, J = 15.32,
6.38 Hz); 8.38 (q, 2H, J = 12.75, 7.36 Hz); 8.05 (q, 1H, J = 8.32,
3.08 Hz); 7.83 (q, 1H, J = 8.22, 2.98 Hz); 7.75 (q, 1H, J = 7.86,
2.24 Hz). Electronic spectra kmax nm (e mol1 dm3 cm1, 50%
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(15996).
2.4.3. Resolution of [Ru(phen)2(phendo)](PF6)2
The D- and K-isomers of [Ru(phen)2(phendo)](PF6)2 were syn-
thesised using the method by Hiort et al. [15].
D-[Ru(phen)2(phendo)](PF6)2 (0.18 g, 39%). CD (H2O:CH3CN,
1.5  106 M, RT.): k nm (De mdeg M cm): 256 (65.2), 267
(113.2), 296 (61.3), 410 (9.2), 460 (7.1).
K-[Ru(phen)2(phendo)](PF6)2 (0.10 g, 22%). CD (H2O:CH3CN,
1.5  106 M, RT.): k nm (De mdeg M cm): 256 (54.6), 267
(94.7), 296 (51.9), 410 (7.8), 4604 (6.0).
2.5. Synthesis of HSP-2, HSP-6 and RUP1
2.5.1. Synthesis of polyamides (general method) [11a]
Fmoc-b-alanine-chlorotrityl resin was prepared by the addition
of Fmoc-b-alanine-OH to 2-chloro-chlorotrityl resin. The next step
of the reaction was undertaken by machine assisted protocol. The
Fmoc-protected amino group of the b-alanine resin was removed
by the addition of 20% piperidine in DMF (10 mL). This was fol-
lowed by the addition of an activated monomer to the resin, allow-
ing a mix time from 3.5 to 9 h depending upon the monomer used.
The resin was ﬁltered and washed with DMF (2  10 mL), DCM
(10 mL) and DMF (10 mL). The amino group was deprotected and
the cycle of addition, mixing and deprotection commenced and
continued until the desired polyamide was formed.
2.5.2. Resin preparation
Fmoc-b-alanine-OH (0.15 g, 0.48 mmol) was added to DIEA
(0.35 mL) in anhydrous DCM (4 mL) and the solution was stirred
for 5 min. It was then added to a suspension of 2-chloro-chlorotri-
tyl resin (0.50 g, 0.50 mmol) in anhydrous DCM (3 mL) and stirred
gently for 5.5 h. MeOH (2.5 mL) was added and the suspension was
stirred for a further 0.5 h. The solution was ﬁltered and the solid
resin was air dried for 12 h.
2.5.3. Activation of monomers and coupling (general method)
The monomer or linker of choice was dissolved in a mixture of
DMF and NMP followed by the addition of the coupling agent,
HBTU. DIEA was added and the solution was stirred for 10 min.
The activated monomer was added manually to the resin and the
suspension was mixed for any time between 3.5 - 9 h, whilst being
aspirated with N2(g). The resin was ﬁltered, washed with DMF
(10 mL), treated with 20% piperidine in DMF (10 mL) and washed
with DCM (2  10 mL) and DMF (3  10 mL). The speciﬁc mono-
mers, activation conditions and coupling times for speciﬁc DNA
base-pair sequences are shown in Tables 1–3.
2.5.4. Polyamide cleavage (general method)
Once prepared, the polyamides were cleaved from the resin by
adding a solution of DCM (10 mL), triﬂuoroethanol (TFE, 2.4 mL)
and acetic acid (1.2 mL) and shaken gently for 1.5 h. The resin
was removed by ﬁltration and washed with TFE:DCM (1:4, 6 mL)
before it was subjected to the cleaving conditions twice more.
The yellow/brown ﬁltrate was collected and the solvent was re-
moved under reduced pressure to 2 mL. Cold diethyl etherTable 1
The activation conditions used for the monomers for the synthesis of b-Ala-Py-L4-Im.
Monomer/linker Mass (mg) Moles (mmol) DM
PyE 86.97 0.24 3
Fmoc-c-aminobutyric acid linker 87.21 0.27 3
ImE 78.08 0.22 4(4 mL) was added and the mixture cooled to 4 C for 1.5 h to pre-
cipitate a yellow solid. The solvent was decanted and water
(3 mL) was added to the solid before the solution was lyophilised
to yield the desired polyamide.
2.5.5. Synthesis of b-Ala-Py-L4-Im
The polyamide was cleaved from the resin, as previously de-
scribed, to obtain a pale yellow powder (0.08 g, 67%). 1H NMR
300 MHz (d6-DMSO): d 9.74 (s, 1H), 8.41 (t, 1H, J = 5.8 Hz), 7.99
(t, 1H, J = 5.5 Hz), 7.31 (s, 1H), 7.07 (s, 1H), 6.95 (s, 1H), 6.62 (s,
1H), 3.92 (s, 3H), 3.75 (s, 3H), 3.34 (q, 2H, J = 7.0 Hz), 3.24 (q, 2H,
J = 7.2 Hz), 2.42 (t, 2H, J = 7.2 Hz), 2.22 (t, 2H, J = 7.4 Hz), 1.77 (m,
2H, J = 7.1 Hz).
2.5.6. Synthesis of HSP-2
b-Ala-Py-L4-Im (0.05 g, 0.12 mmol) in DMF (100 mL) was acti-
vated using HBTU (0.04 mg, 0.12 mmol) and DIEA (0.06 mL,
0.35 mmol). The solution was stirred for 5 min before Pt-L6-NH2
(0.025 mg, 0.07 mmol) was added and the mixture stirred over-
night under N2(g). The solvent was removed under reduced pres-
sure before the addition of acetone to precipitate the product as
a slightly yellow coloured powder (0.04 mg, 72.9%). 1H NMR
300 MHz (d6-DMSO): d 9.73 (s, 1H), 8.40 (t, 1H, J = 5.8 Hz), 7.92
(t, 1H, J = 5.5 Hz), 7.83 (t, 1H, J = 5.6 Hz), 7.31 (s, 1H), 7.07 (s, 1H),
6.96 (s, 1H), 6.61 (s, 1H), 5.41 (bp, 2H), 4.00 (s, 6H), 3.92 (s, 3H),
3.75 (s, 3H), 3.34 (q, 2H, J = 7.0 Hz), 3.24 (q, 2H, J = 7.2 Hz), 3.02
(q, 2H, J = 6.7 Hz), 2.50 (bm, 2H), 2.42 (t, 2H, J = 7.2 Hz), 2.22 (t,
2H, J = 7.4 Hz), 1.77 (p, 2H, J = 7.1 Hz); 195Pt NMR 85 MHz (d7-
DMF): -2425 (bs). Anal. Calc. for C24H44Cl2N10O4PtH2O: C, 35.12;
H, 5.65; N, 17.07%; Found: C, 35.44; H, 5.64; N, 16.67%. ESI-MS Calc.
for C24H44ClN10O4Pt [MCl] 767.2 m/z; found 767.2 m/z. Elec-
tronic spectra kmax nm (e mol1 dm3 cm1, 50% CH3CN in H2O):
220 (68000), 260 (16794), 290 (25950), 435 (15996).
2.5.7. Synthesis of b-Ala-PyPyPy-L4-ImImIm
b-Ala-PyPyPy-L4-ImImIm was cleaved from the resin using the
general procedure described for chlorotrityl resin polyamide cleav-
age. The procedure was carried out twice to obtain a pale yellow
powder (0.20 g, 80%). 1H NMR 300 MHz (d6-DMSO): d 10.00 (s,
1H), 9.84 (s, 1H), 9.83 (s, 1H), 9.78 (s, 1H), 9.57 (s, 1H), 8.30 (t,
1H, J = 5.8 Hz), 7.96 (t, 1H, J = 5.4 Hz), 7.63 (s, 1H), 7.51 (s, 1H),
7.43 (s, 1H), 7.21 (d, 1H, J = 1.4 Hz), 7.17 (d, 1H, J = 1.4 Hz), 7.15
(d, 1H, J = 1.4 Hz), 7.07 (s, 1H), 7.03 (d, 1H, J = 1.4 Hz), 6.88 (d,
1H, J = 1.6 Hz), 6.85 (d, 1H, J = 1.6 Hz), 4.03 (s, 3H), 4.00 (s, 3H),
3.96 (s, 3H), 3.84 (s, 3H), 3.83 (s, 3H), 3.80 (s, 3H), 3.39 (t, 2H,
J = 7.0 Hz), 3.37 (q, 2H, J = 7.3 Hz), 2.47 (t, 2H, J = 7.1 Hz), 2.29 (t,
2H, J = 7.4 Hz), 1.82 (m, 2H, J = 7.1 Hz).
2.5.8. Synthesis of HSP-6
b-Ala-PyPyPy-L4-ImImIm (0.07 g, 0.18 mmol), in DMF was acti-
vated using HBTU (0.03 mg, 0.07 mmol) and DIEA (0.04 mL,
0.22 mmol). The solution was stirred for 5 min before Pt-L6-NH2
(0.02 mg, 0.05 mmol) was added and the mixture stirred overnight
under N2(g). The solvent was removed under reduced pressure be-
fore acetone was added to precipitate the product. HSP-6 (59 mg,
86.4%) was obtained as a slightly yellow coloured powder. 1H
NMR 300 MHz (d6-DMSO): d 9.98 (s, 1H), 9.84 (s, 1H), 9.83 (s,F (mL) NMP (mL) HBTU (mg) DIEA (mL) Time (h)
3 83.28 0.12 3.5
3 83.28 0.12 4
2 83.28 0.12 5
Table 2
The activation conditions used for the monomers for the synthesis of b-Ala-PyPyPy-L4-ImImIm.
Monomer/linker Mass (mg) Moles (mmol) DMF (mL) NMP (mL) HBTU (mg) DIEA (mL) Time (h)
PyE 86.97 0.24 3 3 83.28 0.12 3.5
PyE 86.97 0.24 3 3 83.28 0.12 3.5
PyE 86.97 0.24 3 3 83.28 0.12 3.5
Fmoc-c-aminobutyric acid linker 87.21 0.27 3 3 83.28 0.12 3.5
ImE 78.08 0.22 4 2 83.28 0.12 5
ImE 78.08 0.22 4 2 83.28 0.12 9
ImE 78.08 0.22 4 2 83.28 0.12 9
Table 3
The activation conditions used for the monomers for the synthesis of D- and -RUP1.
Monomer/linker Mass (mg) Moles (mmol) DMF (mL) NMP (mL) HBTU (mg) DIEA (mL) Time (h)
PyE 86.97 0.24 3 3 83.28 0.12 3.5
Fmoc-c-aminobutyric acid linker 87.21 0.27 3 3 83.28 0.12 4
ImE 78.08 0.22 4 2 83.28 0.12 4.5
Fmoc-b-alanine linker 74.72 0.24 4 2 83.28 0.12 4
Fmoc-DAP(Fmoc)-OH 131.65 0.25 3 3 83.28 0.12 7
K- or D-[Ru(phen)2(phendo)](PF6)2 200.00 0.21 5 – – – 5
N. Orkey et al. / Inorganica Chimica Acta 393 (2012) 187–197 1911H), 9.78 (s, 1H), 9.57 (s, 1H), 8.28 (t, 1H, J = 5.8 Hz), 7.93 (t, 1H,
J = 5.4 Hz), 7.81 (t, 1H, J = 5.4 Hz), 7.61 (s, 1H), 7.49 (s, 1H), 7.42
(s, 1H), 7.21 (d, 1H, J = 1.4 Hz), 7.17 (d, 1H, J = 1.4 Hz), 7.15 (d,
1H, J = 1.4 Hz), 7.07 (s, 1H), 7.03 (d, 1H, J = 1.4 Hz), 6.87 (d, 1H,
J = 1.6 Hz), 6.83 (d, 1H, J = 1.6 Hz), 5.19 (bp, 2H), 4.03 (s, 3H), 4.98
(s, 3H), 3.94 (s, 3H), 3.82 (s, 3H), 3.81 (s, 3H), 3.78 (s, 3H), 3.39 (t,
2H), 3.37 (q, 2H, J = 7.3 Hz), 3.02 (q, 2H, J = 7.1 Hz), 2.47 (t, 2H,
J = 7.1 Hz), 2.29 (m, 4H, J = 7.4 Hz), 1.82 (p, 2H, J = 7.1 Hz); 195Pt
NMR 85 MHz (d7-DMF): 2420 (bs). Anal. Calc. for
C46H66Cl2N20O8Pt6H2O2.5C3H7NO: C, 40.57; H, 6.08; N, 19.90%;
Found: C, 40.84; H, 5.76; N, 19.66%. ESI-MS Calc. for
C46H66ClN20O8Pt [MCl]+ 1257.6 m/z; found 1257.4 m/z.2.5.9. Synthesis of D- and -RUP1
D-RUP1: 1H NMR 400 MHz (d6-DMSO): d 10.05 (d, 1H,
J = 8.03 Hz); 9.86 (s, 1H); 9.81 (s, 1H); 9.58 (d, 1H, J = 8.81 Hz);
8.85 (s, 2H); 8.46 (s, 2H); 8.29 (s, 2H); 8.13 (s, 1H); 8.06 (s, 1H);
7.99 (s, 1H); 7.84 (s, 2H); 7.44 (s, 1H); 7.13 (s, 1H); 6.67 (s, 1H);
3.96 (s, 1H); 3.82 (s, 3H); 3.39 (s, 2H); 3.32 (s, 2H); 2.41 (s, 2H);
2.31 (s, 2H); 1.83 (s, 2H). ESI-MS Calc. for C60H52N16O7Ru expected
(m/z): 605.30; found (m/z): 605.12. CD (H2O:CH3CN, 1.5  106 M,
RT.): k nm (De mdeg M cm1): 256 (86.3), 267 (156.3), 296
(35.6), 410 (5.8), 460 (6.7). Electronic spectra kmax nm (e
mol1 dm3 cm1, 50% CH3CN in H2O): 263 (1.2  105), 444
(1.7  104).
K-RUP1: 1H NMR 400 MHz (d6-DMSO): d 10.03 (d, 1H,
J = 8.03 Hz), 9.87 (s, 1H), 9.78 (s, 1H), 9.60 (d, 1H, J = 7.81 Hz),
8.85 (d, 2H, J = 7.74 Hz), 8.46 (s, 2H), 8.31 (s, 2H), 8.26 (s, 1H),
8.13 (s, 1H), 8.00 (m, 2H), 7.84 (s, 2H), 7.47 (s, 1H), 7.13 (s, 1H),
6.69 (s, 1H), 3.95 (s, 1H), 3.83 (s, 3H), 2.95 (s, 2H), 2.83 (s, 2H),
2.49 (s, 2H), 2.31 (s, 2H), 1.84 (m, 2H). ESI-MS Calc. for
C60H52N16O7Ru expected (m/z): 605.30; Found (m/z): 605.12%. CD
(H2O:CH3CN, 1.5  106 M, RT.): k nm (De mdeg M cm1): 256
(82.8), 267 (143.5), 296 (33.9), 410 (5.6), 460 (6.4). Electronic
spectra kmax nm (e mol1 dm3 cm1, 50% CH3CN in H2O): 263
(1.2  105), 444 (1.7  104).2.6. Biological studies
2.6.1. Cytotoxicity
IC50 testing was conducted on the metallopolyamide complexes
using the L1210 murine luekemia cell line are the results for
growth inhibition studies of compounds using the Coulter Count-ing (CC) assay. These tests were conducted at the Andrew Durant
drug testing facility at the Peter MacCullum Cancer Institute. The
metallopolyamide complexes were dissolved in DMSO prior to
use. L1210 cells were exposed to the complexes for 48 h and the
experiments were carried out in duplicate.
2.6.2. LD studies of DNA binding afﬁnity
Couette ﬂow cell was used to measure the interactions between
ct-DNA and the ruthenium complexes. Phosphate buffer (10 mM,
pH 7) with sodium ﬂuoride (20 mM) was used throughout the LD
experiments. Sodium ﬂuoride was chosen as it does not absorb at
low wavelengths (<200 nm) like sodium chloride [16]. To calculate
the concentration of ct-DNA, a molar extinction value at 260 nm of
e = 13200 mol1 cm1 was used [17]. ct-DNA (700 lL, 50 lM) was
placed in a Couette ﬂow cell and the inner cylinder was rotated
(2 V) to orient ct-DNA and a LD spectrum was recorded. Fifteen
samples were prepared, with increasing metal complex and a con-
stant ct-DNA concentration (as shown in Supplementary data), and
allowed to equilibrate overnight at 25 C. The LD of these samples
both spinning and non-spinning was measured. The non-spinning
measurement was subtracted from the spinning to correct for
background noise. The LD spectrum of ct-DNA was subtracted from
the sample spectrum to obtain a difference LD for each sample. All
binding experiments were performed in duplicates.3. Results and discussion
3.1. Synthesis and characterisation of HSP-2
The synthesis of b-Ala-Py-L4-Im (shown in Fig. 3) was achieved
using Fmoc-b-alanine-chlorotrityl resin. The polyamide was
cleaved from the resin using acetic acid and TFE before it was
lyophilized to obtain a yellow powder (67%). HSP-2 was produced
by combining the polyamide, b-Ala-Py-L4-Im at Pt-L6-NH2 through
solution phase chemistry. The product was obtained in a yield of
67.2% (see Fig. 4).
The b-alanine monomer attached to the resin was deprotected
by the addition of 20% piperidine in DMF. This removed the
Fmoc-protecting group, resulting in a free –NH2. In a separate ves-
sel, PyE was dissolved in DMF/NMP mixture (1:1 v/v) and activated
by the addition of HBTU and DIEA. HBTU itself needs to be acti-
vated by the addition of DIEA [18]. This mixture was stirred for
5 min. HBTU forms a temporary bond with PyE by displacing
Fig. 3. The summary of the synthesis of HSP-2. The reaction conditions used were (i) DIEA, Fmoc-b-alanine-OH, 5 h; (ii) 20% piperidine in DMF, PyE, 3.5 h; (iii) 20% piperidine
in DMF, Fmoc-c-aminobutyric acid, 4 h; (iv) 20% piperidine in DMF, Im, 4.5 h; (v) TFE/acetic acid/DCM (2:1:7 v/v) mixture, 2 h; (vi) activated b-Ala-Py-L4-Im was stirred with
Pt-L6-NH2 overnight.
ppm (t1)
1.02.03.04.05.06.07.08.09.010.0
NH 
3 × NH 
1,2,9,11
H22
H23 & H24 
H3 & H10 
11 × CH2
DMSO
HDO
NH2Pt
NH3
Cl
NH3
N
N
NH
O
O
N
H
N
O
H
N
H
N
O
1
2
4
5
6
7
8
9
10
1112
13
14
15
16
17
18
19
20
21
22
23
24
3
Fig. 4. The chemical structure of HSP-2 along with the 195Pt and 1H NMR spectrum in d6-DMSO at 35 C with labelled proton resonances.
192 N. Orkey et al. / Inorganica Chimica Acta 393 (2012) 187–197the –OH group. The activated solution of PyE was added to the re-
sin and the suspension was stirred for 3.5 h under N2(g). This en-
sured that most of the activated PyE would react with the b-
alanine group on the resin. The free amine group on the b-alanine
displaced the HBTU group to form a peptide bond between PyE and
b-alanine.
One amide singlet, at 9.73 ppm, was observed for the proton la-
belled 8 in the 1H NMR of HSP-2. Three amide triplets at 8.40, 7.92
and 7.83 ppm correspond to the protons labelled 4, 12 and 16,respectively. The four aromatic protons 1, 2, 9, and 11 were as-
signed to the four singlets at 7.31, 7.07, 6.96 and 6.61 ppm. The
NH2 directly coordinated to the platinum(II) centre was observed
as a broad peak at 5.41 ppm, while the two platinum(II)-bound
NH3 groups were observed together as a broad singlet at
4.00 ppm. The two singlets at 3.92 and 3.75 ppm were assigned
as the two methyl groups labelled 3 and 10. The eleven CH2 groups
were observed in the aliphatic region between 1.77 and 3.34 ppm.
The peak of the platinum(II) was observed at 2425 ppm as a
N. Orkey et al. / Inorganica Chimica Acta 393 (2012) 187–197 193broad singlet. ESI-MS gave a parent peak corresponding to the sin-
gly charged ion HSP-2+ in aqueous solution. The purity of HSP-2
was assessed by elemental analysis; with the analysis indicating
that HSP-2 contains one H2O of hydration.3.2. Synthesis and characterisation of HSP-6
3.2. Synthesis and characterisation of HSP-6
The synthesis of HSP-6 was achieved in an overall yield of 69.1%
in a similar stepwise assembly as shown for HSP-2 in Fig. 3. The 1H
NMR spectrum of HSP-6 (Fig. 5) shows ﬁve amide singlets between
9.98 and 9.57 ppm which correspond to protons labelled 7, 17/21,
4, and 13, respectively. Three amide triplets at 8.28, 7.93 and
7.81 ppm correspond to 9, 25 and 38, respectively. The ten sing-
lets/doublets between 7.61 and 6.83 ppm correspond to the ten
aromatic protons. The terminal –NH2 group is observed as a broad
peak at 5.19 ppmwhile the six singlets between 4.03 and 3.78 ppm
correspond to the 6  N–CH3 groups. The 2  –NH3 groups reso-
nate at the same frequency as the N–CH3 groups and thereforeNH2
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region between 3.39 and 1.82 ppm. The 195Pt NMR spectrum of
HSP-6 shows a single platinum resonance at 2420 ppm. The
chemical shift is consistent with similar metal complexes with
PtN3Cl coordination spheres [4b,19]. Both HSP-2 and HSP-6 dis-
played poor solubility in aqueous solutions; as a result both com-
plexes were dissolved in 1% DMSO in water/ACN (1:1, v/v) for the
purposes of mass spectrometry. In the ESI mass spectrum of HSP-6,
there is one prominent ion peak which occurs at m/z 1,257.4 and
corresponds to the parent metal complex with the 1+ charge. Frag-
mentation ions are also observed. The peak at m/z 993.4 can be as-
signed to the metal complex minus the trans-chlorodiamine
platinum group.3.3. Synthesis and characterisation of D- and K-RUP1
[Ru(phen)2(phendo)]2+ was chosen as the ruthenium precursor
because the resolution of this complex had already been reported
by Hiort et al. [15]. It was also essential that a ruthenium(II) inter-
mediate that included a phendo ligand be used (resolved) to attachN
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K-[Ru(phen)2(phendo)]2+ complexes isolated using the published
method were in this instance of greater enantiomeric purity that
had previously reported [15]. RUP1 was synthesised by solid phase
chemistry using the chlorotrityl resin in a stepwise procedure as
shown in Fig. 6. The synthesis was initiated with the preparation
of the resin.
The monomers/linkers, Fmoc-c-aminobutyric acid linker, ImE,
Fmoc-b-alanine-OH and Fmoc-DAP-(Fmoc)-OH were added to the
resin in a similar manner, after being activated with HBTU after
the previous attached monomer/linker had been deprotected. The
ﬁnal step saw the addition of either K- or D-[Ru(phen)2(phen-Cl
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Fig. 6. The summary of the synthesis of K- and D-RUP1. The reaction conditions used w
piperidine in DMF, Fmoc-c-aminobutyric acid, 4 h; (iv) 20% piperidine in DMF, ImE, 4.5
Fmoc-DAP-(Fmoc)-OH, 7 h; (vii) 20% piperidine in DMF, D- or K-[Ru(phen)2(phendo)](Pdo)](PF6)2 to the resin. Once the desired polyamide metal complex
was synthesised, the resin was thoroughly washed with DCM,
DMF, diethylether, H2O, acetone and EtOH, to remove all unreacted
materials, and dried under N2(g). The complex was then cleaved
from the resin by the addition of TFE/acetic acid/DCM (2:1:7, v/v)
mixture. The orange product was characterised by 1H NMR, NOESY
and ESI/MS.
From the 1H NMR in Fig. 7 it can be seen that H4 and H7, and H5
and H6 are in the same chemical environment and correspond to
the two signals; a doublet at 8.84 ppm (H4 and H7) and a singlet
8.46 ppm (H5 and H6). The methyl groups on the Im and Py rings
resonate as singlets at 3.95 and 3.82 ppm respectively. The methyl.Fmoc O
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Fig. 7. The chemical structure of K-RUP1 along with the 1H NMR spectrum in d6-DMSO at 35 C with labelled proton resonances.
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and H23 (at 7.4 and 7.1 ppm), which correspond to the aromatic
protons on the Im and Py rings respectively. D-RUP1 was charac-
terised using 1H NMR and NOESY and is identical to the K-isomer
(Supplementary data).
ESI/MS experiments for the K- and D-RUP1 isomers showed
that both complexes contain the parent ions carrying a 2+ charge
of 605.3 (m/z), which was consistent with the theoretical value cal-
culated (605.12 (m/z). When the UV spectra of RUP1 was compared
to [Ru(phen)2(dpq)]2+ (Fig. 8), it was evident that that both com-
plexes have similar transitions, with a broad metal centred transi-
tion at 450 nm, a sharp n–p⁄ transition at 265 nm with a shoulder
at approximately 300 nm [21]. The contribution of the polyamide
to these transitions was made evident from a difference UVFig. 8. The UV–Vis spectrum of RUP1 (A) and rac-[Ru(phen)2(dpq)]2+ (B) the insert
shows a spectrum where UV (B) is subtracted from UV (A) this represents the
polyamide contribution to the spectrum (C) in H2O:acetonitrile (1:1 v/v) mixture at
room temperature. The concentration of both complexes was 10 lM.spectra, produced by subtracting the UV of [Ru(phen)2(dpq)]2+
from that of RUP1. The method used to obtain the extinction co-
efﬁcient for RUP1 is shown in the Supplementary data ⁄⁄(Figure
S3 and Table 1).
The chirality of the metal precursors, D- orK-[Ru(phen)2(phen-
do)]2+ was conserved and is apparent in the CD of the products D-
andK-RUP1. As the structure of either D- or K-[Ru(phen)2(dpq)]2+
make up the metal complexes component of the polyamide, their
CD spectra were compared with to D- and K-RUP1. Slight changes
in the wavelengths of the peaks were observed but more signiﬁ-
cantly there are changes in the intensities of these peaks which
can be attributed to the inﬂuence of the polyamide (Fig. 9).Fig. 9. The CD spectrum of K-RUP1 (A) and D-RUP1 (B), in comparison to K-
[Ru(phen)2(phendo)]2+ (A0) and D-[Ru(phen)2(phendo)]2+ (Bh) at 10 lM in
H2O:acetonitrile (1:1 v/v) mixture.
Fig. 10. (A) LD spectra of LD-DNA titration with D-RUP1 (left) and K-RUP1 (right). (B) LD spectra where the DNA spectrum has been subtracted from each LD-DNA titration
spectrum of D-RUP1 (left) and K-RUP1 (right).The wavelength (nm) is plotted on the X-axis, while the MC complex concentration (M) on the Y- and the LD (dOD) on the Z-
axis respectively.
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3.4.1. In vitro testing. In vitro testing was conducted using L1210
murine leukaemia cells however HSP-2 and HSP-6 were not sufﬁ-
ciently soluble, even when dissolved in a small amount of DMSO or
DMF, and precipitated out of the aqueous medium used for assays.
As a result of this, the IC50 values of the platinum metallopolya-
mide complexes could not be determined. Ruthenium(II) com-
plexes are not largely known for their cytotoxicity [22]. However,
these tests were performed to evaluate the effect of the sequence
selective ‘tail’ part of the molecule on overall cytotoxicity. Neither
D nor K-RUP1 exhibited cytotoxicity with IC50 values >40 lM re-
quired to inhibit cell growth.3.4.2. LD studies of DNA binding afﬁnity. Previously, a 1H NMR study
conducted by Greguric et al. [23] reported that the D-[Ru(-
phen)2(dpq)]2+ complex interacted with a hexanucleotide through
the minor groove by intercalation. Linear dichroism studies con-
ducted by Lincoln et al. [24] indicated that the analogous [Ru(-
phen)2(dppz)]2+ complex intercalated within the DNA base pairs.
The LD spectra of ct-DNA with the D- and K-[Ru(phen)2(dpq)]2+
and D- and K-isomers of RUP1 were measured and the resulting
spectra compared. The initial LD spectrum of DNA shows a distinc-
tive negative peak at 260 nm which is indicative of the p–p⁄ tran-
sitions of the DNA. Changes in the LD spectra that are produced
upon the titration of D-[Ru(phen)2(dpq)]2+ into DNA shows that
the negative intensity below 300 nm becomes more positive.
Whereas the positive peak at 380 nm and the negative peak at
480 nm, due to MLCT of the metal complex, grow in intensity with
increasing concentration (Supplementary data Fig. S4). The LD
spectra of the titration of K-[Ru(phen)2(dpq)]2+ with DNA showssimilar signals but with greater intensity at 380 and 480 nm (Sup-
plementary data Fig. S4).
The LD transitions for D-RUP1 when bound to DNA, shows a de-
crease in intensity at 258 nm and a small positive at 264 nm which
could indicate groove binding (Fig. 10A and B, left). Two small LD
bands in the visible region are also evident with both the positive
band centered at 380 nm and the negative band at 480 nm of sim-
ilar magnitude like D-[Ru(phen)2(dpq)]2+. The difference LD shown
in Fig. 10B, clearly shows the relative changes. When bound to
DNA, K-RUP1 also shows a decrease in intensity in the LD spec-
trum at 268 nm with a shoulder at 288 nm and a positive signal
at 325 nm (Fig. 10A and B, right). The signals due to MLCT of K-
RUP1 grow in intensity with increasing concentration and are lar-
ger than seen for D-RUP1. Moreover the broad positive band at
380–430 nm is larger in intensity relative to the negative band at
480 nm. This evidence would suggest that groove binding is the
mode of interaction for both D- and K-RUP1.4. Conclusion
Four metallopolyamide complexes, two platinum(II) complexes
– [Cl(NH3)2Pt-L6-b-Ala-Py-L4-Im]+ (HSP-2) and [Cl(NH3)2Pt-L6-b-
Ala-PyPyPy-L4-ImImIm]+ (HSP-6), along with two ruthenium enan-
tiomers, D and K-[b-Ala-Py-L4-Im-b-dpq-Ru(phen)2]2+ (D and K-
RUP1), were successfully synthesised in good yield by a combina-
tion of solid and solution phase chemistries. Characterisation was
achieved using NMR and ESI-MS. CD for D- and K-RUP1. Con-
ﬁrmed that the chirality of the ruthenium precursors D- and K-
[Ru(phen)2(phendo)]2+ was conserved throughout the synthesis.
Cytotoxicity and binding interactions were not determined for
N. Orkey et al. / Inorganica Chimica Acta 393 (2012) 187–197 197HSP-2 or HSP-6, which although isolated, were poorly soluble in
aqueous solution inhibiting testing. Since the IC50 value of D and
K-RUP1 were greater than 40 lM they have potential to be used
as DNA probes. LD studies indicated that the ruthenium complexes
interact with ct-DNA through a mixed binding mode, which is
inﬂuenced by complex concentration and chirality.
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